- Home
- HURN vs PTGX Comparison
HURN vs PTGX Comparison
Compare HURN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- PTGX
- Stock Information
- Founded
- HURN 2002
- PTGX 2006
- Country
- HURN United States
- PTGX United States
- Employees
- HURN N/A
- PTGX N/A
- Industry
- HURN Professional Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- PTGX Health Care
- Exchange
- HURN Nasdaq
- PTGX Nasdaq
- Market Cap
- HURN 2.6B
- PTGX 2.8B
- IPO Year
- HURN 2004
- PTGX 2016
- Fundamental
- Price
- HURN $150.46
- PTGX $42.97
- Analyst Decision
- HURN Strong Buy
- PTGX Strong Buy
- Analyst Count
- HURN 5
- PTGX 8
- Target Price
- HURN $158.60
- PTGX $66.50
- AVG Volume (30 Days)
- HURN 240.0K
- PTGX 990.2K
- Earning Date
- HURN 04-29-2025
- PTGX 05-06-2025
- Dividend Yield
- HURN N/A
- PTGX N/A
- EPS Growth
- HURN 92.74
- PTGX N/A
- EPS
- HURN 6.67
- PTGX 0.86
- Revenue
- HURN $1,525,814,000.00
- PTGX $207,801,000.00
- Revenue This Year
- HURN $11.10
- PTGX N/A
- Revenue Next Year
- HURN $6.72
- PTGX $7.13
- P/E Ratio
- HURN $22.70
- PTGX $50.68
- Revenue Growth
- HURN 8.98
- PTGX N/A
- 52 Week Low
- HURN $84.87
- PTGX $24.22
- 52 Week High
- HURN $153.85
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- HURN 63.36
- PTGX 43.08
- Support Level
- HURN $122.32
- PTGX $41.29
- Resistance Level
- HURN $154.83
- PTGX $46.12
- Average True Range (ATR)
- HURN 4.98
- PTGX 1.83
- MACD
- HURN 1.67
- PTGX -0.19
- Stochastic Oscillator
- HURN 86.56
- PTGX 27.81
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.